The Impact of COVID-19 on Cancer

Li, Yue; Wang, Xingjian; Wang, Wei

doi:10.2147/idr.s324569

Cited by 22 publications

(18 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the recent SARS-CoV-2 pandemic may have a negative impact on mortality tendencies observed in the next few years because of postponed screening and diagnostic processes and treatment delays. 59 Moreover, continually increasing rates of CUC incidence and mortality and trends of increased BC incidence might be expected as a result of observed socioeconomic changes, predicted increases in obesity prevalence, and the exhaustion or lack of viable screening methods. 60 Nevertheless, increasing awareness, growing recognition of screening importance, and the introduction of new accessible therapeutic options may eventually lead to more favorable tendencies in the future.…”

Section: Discussionmentioning

confidence: 99%

Trends in Incidence and Mortality of Gynecological and Breast Cancers in Poland (1980–2018)

Piechocki¹,

Koziołek²,

Sroka³

et al. 2022

CLEP

View full text Add to dashboard Cite

Background This study aimed to analyze and determine the incidence and mortality trends in gynecological and breast cancers (BCs) in Poland. The gynecological cancers assessed were cervical cancer (CC), corpus uteri cancer (CUC), ovarian cancer (OC), vaginal cancer (VAC), and vulvar cancer (VUC). Patients and Methods Data concerning the incidence and mortality for the period of 1980–2018 were obtained from the Polish National Cancer Registry (PNCR). Joinpoint regression analysis was performed to identify trends, which were described using the annual percentage change (APC) and the average annual percent change (AAPC). Results Statistically significant increases were observed in BC incidence (AAPC: 2.3; CI: 1.8 to 2.9; p<0.05), CUC incidence (AAPC: 2.3; CI: 1.9 to 2.7; p<0.05), CUC mortality (AAPC: 0.4; CI: 0.1 to 0.7; p<0.05) and VUC mortality (AAPC: 1.16, CI: 0.1 to 2.2; p<0.05). VAC mortality decreased (AAPC: −3.5, CI: −5.0 to –2.0; p<0.05), as did CC incidence and mortality (AAPC: −2.1, CI: −2.3 to −1.8; p<0.05, AAPC: −2.0, CI: −2.2 to –1.8; p<0.05, respectively). Between 1980 and 1993, OC incidence initially increased and then stabilized (AAPC: 0.9; CI: 0.7 to 1.1; p<0.05). After 2007, OC mortality decreased (AAPC: 0.0; CI: −0.2 to 0.2; p=0.8). Trends in VUC and VAC incidence and BC mortality were not statistically significant. Conclusion The results of this study showed a significant increase in OC, CUC, and BC incidence, and a decrease in the incidence of CC and VAC. The VUC trends were stable. Mortality trends for BC initially fluctuated and, since 2010, has begun to increase. Throughout the observed period, mortality due to VUC and CUC increased, whereas decreased among patients with CC. OC mortality was stable, but not significant. Furthermore, the study showed a correlation between age group and rate of incidence and mortality of each assessed cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Trends in Incidence and Mortality of Gynecological and Breast Cancers in Poland (1980–2018)

Piechocki¹,

Koziołek²,

Sroka³

et al. 2022

CLEP

View full text Add to dashboard Cite

show abstract

“…The effects of the pandemic on clinical trials were felt throughout administrative and clinical practices. Clinical trial initiation and recruitment were typically halted at the beginning of the pandemic as infection control measures were implemented [ 38 ]. Furthermore, trials of investigational medical products (IMPs) known to be immune-suppressive, or cause pneumonitis, were ceased due to concerns about the potential to exacerbate the severity of SARS-CoV-2 infection [ 39 ].…”

Section: Impact On Clinical Trialsmentioning

confidence: 99%

The Impact of the COVID-19 Pandemic on Oncology Care and Clinical Trials

Ali

Riches

2021

Cancers

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic has caused considerable global disruption to clinical practice. This article will review the impact that the pandemic has had on oncology clinical trials. It will assess the effect of the COVID-19 situation on the initial presentation and investigation of patients with suspected cancer. It will also review the impact of the pandemic on the subsequent management of cancer patients, and how clinical trial approval, recruitment, and conduct were affected during the pandemic. An intriguing aspect of the pandemic is that clinical trials investigating treatments for COVID-19 and vaccinations against the causative virus, SARS-CoV-2, have been approved and conducted at an unprecedented speed. In light of this, this review will also discuss the potential that this enhanced regulatory environment could have on the running of oncology clinical trials in the future.

show abstract

“…The effects of the pandemic were felt throughout administrative and clinical practices. Clinical trial initiation and recruitment were typically halted at the beginning of the pandemic as infection control measures were implemented [34]. Furthermore, trials of investigational medical products (IMPs) known to be immune-suppressive, or cause pneumonitis, were ceased due to concerns about the potential to exacerbate the severity of SARS-CoV-2 infection [35].…”

Section: Impact On Clinical Trialsmentioning

confidence: 99%

The Impact of the COVID-19 Pandemic on Oncology Care and Clinical Trials

Ali¹,

Riches²

2021

Preprint

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic has caused considerable global disruption to clinical practice. This article will review the impact that the pandemic has had on oncology clinical trials. It will assess the effect of the COVID-19 situation on the initial presentation and investigation of patients with suspected cancer. It will also discuss the impact of the pandemic on the subsequent management of cancer patients and how clinical trial approval, recruitment and conduct were affected during the pandemic. An intriguing aspect of the pandemic is that clinical trials investigating treatments for COVID-19 and vaccinations against the causative virus, SARS-CoV-2, have been approved and conducted at unprecedented speed. In light of this, this re-view will also discuss the potential that this enhanced regulatory environment could have on the running of oncology clinical trials in the future.

show abstract

The Impact of COVID-19 on Cancer

Cited by 22 publications

References 63 publications

Trends in Incidence and Mortality of Gynecological and Breast Cancers in Poland (1980–2018)

Trends in Incidence and Mortality of Gynecological and Breast Cancers in Poland (1980–2018)

The Impact of the COVID-19 Pandemic on Oncology Care and Clinical Trials

The Impact of the COVID-19 Pandemic on Oncology Care and Clinical Trials

Contact Info

Product

Resources

About